NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Enlaza Therapeutics

Enlaza Therapeutics

Private
La Jolla, CaliforniaHealthcare & Life Scienceshttps://enlazatx.com/

Last Round

Strategic

Sep 2, 2025

Total Funding Raised

$161M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Enlaza Therapeutics is a biotechnology company that develops covalent protein therapeutics using its proprietary War-Lock platform to create highly selective biologic drugs for cancer and other serious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

covalent biologicsdrug discovery platformWar-Lockdrug discoverybiotech platformt-cell engagerscovalent chemistrydrug conjugatesnext-gen biologicsautoimmune therapygenetic disease treatmentpreclinical biotechprotein engineeringbiopharma partnershiptherapeutic modalities

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enlaza Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Enlaza Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Enlaza Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicSep 2, 2025
Series AApr 30, 2024
SeedDec 15, 2022

Enlaza Therapeutics Investors

Notable investors and investment history

Enlaza Therapeutics investors
InvestorRounds
A. M. Pappas & AssociatesSeries A
J.P. Morgan Private CapitalSeries A
Frazier Life SciencesSeed, Series A
Avalon VenturesSeries A, Seed
Amgen VenturesSeries A
SamanthaSeries A
Alexandria Venture InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 10, 2025

    $15M raised in early funding.

  • Sep 2, 2025

    Partnered with Vertex Pharmaceuticals on multi-target drug discovery.

Enlaza Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enlaza Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enlaza Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLa Jolla, California
Employee Range68
Year Founded2020
Last FundingSep 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.